Peptide-functionalized nanoparticles and hydrogels show promise for delivering drugs across the eye's protective barriers and supporting retinal cell regeneration in degenerative eye diseases.
Crossing the blood-retinal barrierPeptide-functionalized nanoparticles are engineered to overcome the eye's protective barrier — one of the biggest challenges in treating retinal diseases — enabling targeted drug delivery and cellular regeneration.
What the researchers found
This review examines how peptide-functionalized nanoparticles and nanoscaffolds are being developed to treat degenerative retinal diseases like diabetic retinopathy, age-related macular degeneration (AMD), and retinitis pigmentosa. Key approaches include RGD-modified nanoparticles for receptor-mediated targeting of retinal cells, self-assembling peptide hydrogels that mimic the extracellular matrix to support retinal regeneration, and PEGylated nanostructures that cross the blood-retinal barrier while avoiding immune reactions. Preclinical animal studies have shown promising results for targeted drug delivery, neuroprotection, and stem cell-based regeneration, but scalability, long-term safety, and non-invasive delivery methods remain major challenges.
Why it matters
Degenerative retinal diseases are among the leading causes of irreversible blindness worldwide. Current treatments — like anti-VEGF injections for AMD — require repeated invasive eye injections and can only slow disease progression, not restore lost vision. Peptide-functionalized nanomaterials could overcome this by enabling precisely targeted drug delivery across the blood-retinal barrier, controlled release of therapeutics, and scaffolds that guide retinal cell regeneration. This represents a potential shift from managing vision loss to actually restoring it.
The numbers in context
3 major retinal diseases discussed (diabetic retinopathy, AMD, retinitis pigmentosa) · Multiple peptide-NP platforms reviewed
How the study worked
This is a narrative review examining the chemical design, synthesis, and biomedical applications of peptide-functionalized nanomaterials for retinal diseases. It covers biodegradable polymeric nanoparticles, liposomes, hybrid nanostructures, and self-assembling peptide hydrogels, reviewing their drug delivery mechanisms, cellular interactions, immune modulation properties, and preclinical efficacy data.
Who was studied
Not applicable — review of preclinical research on nanomaterials for retinal disease treatment
What this study cannot tell us
As a review, this article synthesizes existing preclinical research rather than presenting new data. Most evidence comes from animal models with no clinical trials yet conducted for many of the described platforms. Key challenges acknowledged include scalability of manufacturing, long-term safety concerns, and the difficulty of achieving non-invasive delivery to the retina. The review does not systematically assess the quality of the preclinical studies it covers.
How to read the evidence
This is a narrative review of preclinical research. While it covers a wide range of promising technologies, nearly all evidence comes from animal models and in vitro studies. No clinical trial data is presented for the peptide-NP platforms discussed.
When this study was published
Published in 2025, this review captures the cutting edge of peptide-nanotechnology convergence for ophthalmic applications. The field is rapidly evolving, and some technologies discussed may reach early clinical trials in the coming years.
The bigger picture
The eye is one of the most challenging organs for drug delivery, yet it's also one where nanotechnology and peptide engineering could have the greatest impact. Current treatments for retinal diseases are invasive (repeated injections into the eye) and palliative (slowing but not reversing damage). Peptide-functionalized nanomaterials represent a convergence of peptide biology, materials science, and regenerative medicine that could eventually enable non-invasive, targeted, and even restorative therapies for millions of people at risk of blindness.
Questions still open
- Can peptide-functionalized nanoparticles be formulated for non-invasive delivery (eye drops or systemic administration) to avoid repeated intravitreal injections?
- Which peptide-NP combinations are closest to clinical trials for retinal diseases?
- How do the long-term effects of retained nanoparticles in the eye compare to the risks of current intravitreal injection therapies?
Common questions
Why are peptides added to nanoparticles for eye treatments?
When might these treatments be available for patients?
Read the original research
Peptide-functionalized nanomaterials for controlled drug delivery and regenerative therapies in retinal diseases.
Journal of biomaterials applications, 8853282251395196
Citation
Dashti, Razieh; Safaei, Fariba; Sadeghian, Golfam; Hosseini, Seyyed Abed; Salimibani, Milad. (2025). Peptide-functionalized nanomaterials for controlled drug delivery and regenerative therapies in retinal diseases.. Journal of biomaterials applications, 8853282251395196. https://doi.org/10.1177/08853282251395196